Akero Q1 2025 Earnings Report
Key Takeaways
Akero Therapeutics reported a net loss of $70.7 million in the first quarter of 2025, primarily driven by increased R&D expenses for its Phase 3 SYNCHRONY program. The company highlighted positive Phase 2b SYMMETRY study results showing statistically significant reversal of compensated cirrhosis due to MASH with efruxifermin (EFX), and a strong cash position of over $1.1 billion following a public offering in January 2025.
Reported statistically significant reversal of compensated cirrhosis (F4) due to MASH with EFX in the Phase 2b SYMMETRY study.
SYMMETRY study results were published in the New England Journal of Medicine.
Presented new data from SYMMETRY and HARMONY studies at EASL Congress 2025, including analyses with AI-based qFibrosis®.
Completed a follow-on public offering in January 2025, raising approximately $402.5 million in gross proceeds.
Akero
Akero
Forward Guidance
Akero Therapeutics believes its current cash, cash equivalents, and marketable securities are sufficient to fund its operating plan into 2028. Preliminary topline results from the SYNCHRONY Real-World study are expected in the first half of 2026, and 52-week results for primary histology endpoints from the SYNCHRONY Histology study are anticipated in the first half of 2027.
Positive Outlook
- Cash, cash equivalents, and marketable securities are expected to fund operations into 2028.
- Preliminary topline results from the SYNCHRONY Real-World study are on track for the first half of 2026.
- SYNCHRONY Histology study 52-week results for primary histology endpoints are on track for the first half of 2027.
- Ongoing enrollment in the global Phase 3 SYNCHRONY program (N~3,500).
- EFX is being evaluated in three ongoing Phase 3 studies for MASH.
Challenges Ahead
- No specific negative forward-looking guidance was provided in the report.